Neuright Inc., a University of Maine biotech spinoff focused on the early diagnosis and treatment of peripheral neuropathy, was awarded $225,000 under the National Science Foundation’s Small Business Technology Transfer program to develop its technology for delivery to market.
Peripheral neuropathy, a condition in which nerve fibers die back from the skin, is estimated to affect more than 20 million people in the U.S. and can cause symptoms including pain, numbness and loss of limb control, according to a news release.
Diabetes is the leading cause of peripheral neuropathy. Up to 70% of the 34 million Americans with diabetes will also have peripheral neuropathy. Wide-ranging, variable symptoms make peripheral neuropathy difficult to diagnose, and while there is no cure, early intervention and treatment can help patients minimize the often-debilitating effects. Read more